Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 2, 1999, Pages 117-123

  Faivre, Sandrine ^a,b,c   Raymond, Eric ^a,b,c   Woynarowski, Jan M ^b   Cvitkovic, Esteban ^d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CTRC Institute for Drug Development   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔPITAL PAUL BROUSSE   (France)

Author keywords

Combination chemotherapy; Combination index; Diaminocyclohexaneplatinum; Gemcitabine; Nucleoside analogs

Indexed keywords

CISPLATIN; GEMCITABINE; NUCLEOSIDE ANALOG; OXALIPLATIN; PLATINUM DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DEOXYCYTIDINE; DNA; HUMANS; LEUKEMIA; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0032990022     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050955     Document Type: Article

References (37)

1. 1. Abbruzzese JL, Frost P (1992) Studies on the mechanism of the synergistic interaction between 2′ deoxy-5 azacytidine and cisplatin. Cancer Chemother Pharmacol 30: 31-36
2. 2. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B (1990) p53 gene mutation occurs in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722
3. 3. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530
4. 4. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff D (1997) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
5. 5. Byrne MJ, Davidson JA, Musk AW, Dewar J, Hazel G van, Buck M, Klerk N de, Robinson BWS (1998) Cisplatin (C) and gemcitabine (G) treatment for malignant mesothelioma: a phase II study. (abstract 1783) Proc Am Soc Clin Oncol 17: 464A
6. 6. Cheng J, Haas M (1997) Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10: 5502-5509
7. 7. Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H, Cvitkovic E (1996) Single agent activity of oxalixplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 1067-1070
8. 8. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
9. 9. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Cocconi G, Paccagnella A, Adamo V, Incoronato P, Scarcella L, Mosconi AM, Tonato M (1995) Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC). A phase II study (abstract 1066). Proc Am Soc Clin Oncol 14: 352
10. 10. De Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33A: 214-219
11. 11. De las Alas MM, Aebi S, Fink D, Howell SB, Los G (1997) Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 89: 1537-1541
12. 12. Faivre S, Woynarowski JM (1998) Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells (abstract 1081). Proc Am Assoc Cancer Res 39: 158
13. 13. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 56: 4881-4886
14. 14. Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6
15. 15. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJM, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A: 243-248
16. 16. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Tood GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluorodeoxycytidine). Cancer Res 50: 4417-4422
17. 17. Huang P, Chubb S, Hertel L, Grindley GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
18. 18. Kaufmann M, Bauknecht T, Jonat W, Piccart MJ, Van Belle S, Thomas J, Wils JAMJ, Blatter J (1995) Gemcitabine (GEM) in cisplatin-resistant ovarian cancer (abstract 758). Proc Am Soc Clin Oncol 14: 272
19. 19. Kunkel LM, Evans SS, Dottino PR, DiSaia PJ, Nagourney RA (1998) Cisplatin (CDDP) and gemcitabine (DFDC) in relapsed ovarian cancer (abstract 1379). Proc Am Soc Clin Oncol 17: 357A
20. 20. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger F, Gastiaburu J, Misset JL (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous infusion at circadian rhythm modulated rate. Eur J Cancer 29A: 1280-1284
21. 21. Mathe G, Kidani Y, Segiguchi M, Eriguchi MGF, Peytavin G, Misset JL, Brienza S, Vassals F de, Chenu E, Bourut C (1989) Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43: 237-250
22. 22. Misset JL, Chollet P, Vennin P, Laplaige P, Lucas V, Frobert JL, Castera D, Fabbro M, Langlois D, Dupont-Andre G, Otero G, Fandi A (1997) Multicentric phase II-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): toxicity efficacy results (abstract 1266). Proc Am Assoc Clin Oncol 16: 345A
23. 23. Moore MJ, Tannock IF, Ersnt DS, Huan S, Murray N (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445
24. 24. Moore M, Tannock I, Winquist E, Tolcher A, Bennett K, Seymour L (1998) Gemcitabine (GEM) and cisplatin (CIS) is an active regimen for advanced transitional cell carcinoma (TCC): results of a phase II study (abstract 646). Proc NCI-EORTC Symp 10: 169
25. 25. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Braakhuis BJM (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22: 72-79
26. 26. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8: 876-885
27. 27. Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25 [Suppl 5]: 4-12
28. 28. Ren Q, Kerr A, Nguyen D, Kirsch I, Allegra C, Grem J (1997) Gemcitabine-induced cytotoxicity and DNA damage in mismatch-repair deficient colon cancer cells (abstract 682). Proc Am Assoc Cancer Res 38: 102
29. 29. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865
30. 30. Rothenberg ML, Moore MJ, Cripps CM, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassof PG, Brown TD, Casper ES, Storniolo AM, Von Hoff D (1996) A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 7: 347-353
31. 31. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ (1993) 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 46: 762-766
32. 32. Ruschoff J, Bocker T, Schlegel J, Stumm G, Hofstaedter F (1995) Microsatellite instability: new aspects in the carcinogenesis of colorectal carcinoma. Virchows Arch 426: 215-222
33. 33. Skou G, Mangold G, Dexter D, Von Hoff D (1996) Comparison of an oxaliplatin-taxol versus a carboplatin-taxol regimen in the treatment of the MV-522 human lung tumor xenograft (abstract 2558). Proc Am Assoc Cancer Res 37: 374
34. 34. Steward WP, Dunlop DJ, Cameron D, Talbot DC, Kleisbauer JP, Thomas P, Guerin JC, Perol M, Sanson G, Dabouis G, Lacroix H (1995) Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC). A phase I-II study. Eur J Cancer 31A: A1081
35. 35. Tachiro T, Kawada Y, Sakurai Y, Kidani Y (1989) Antitumor activity of a new platinum complex, oxalato (trans-1-1,2,-diaminocyclohexane)platinum(II): new experimental data. Biomed Pharmacother 43: 251-260
36. 36. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum adducts. Cancer Res 58: 3579-3585
37. 37. Zhegari-Squalli N, Misset JL, Cvitkovic E, Goldwasser F (1997) Mechanism of the in vitro synergism between SN38 and oxaliplatin (abstract 20). Proc Am Assoc Cancer Res 38: 3